CN1970034B - Chinese medicine containing gadol and tuckahoe - Google Patents
Chinese medicine containing gadol and tuckahoe Download PDFInfo
- Publication number
- CN1970034B CN1970034B CN2006101618312A CN200610161831A CN1970034B CN 1970034 B CN1970034 B CN 1970034B CN 2006101618312 A CN2006101618312 A CN 2006101618312A CN 200610161831 A CN200610161831 A CN 200610161831A CN 1970034 B CN1970034 B CN 1970034B
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- preparation
- medicine preparation
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims description 139
- 235000008599 Poria cocos Nutrition 0.000 title abstract 2
- 244000248825 Peltandra virginica Species 0.000 title 1
- 235000001188 Peltandra virginica Nutrition 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 75
- 239000008187 granular material Substances 0.000 claims description 61
- 239000000796 flavoring agent Substances 0.000 claims description 32
- 235000019634 flavors Nutrition 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 241000222336 Ganoderma Species 0.000 claims description 24
- 239000009636 Huang Qi Substances 0.000 claims description 21
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 20
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 11
- 238000001694 spray drying Methods 0.000 claims description 10
- 230000006837 decompression Effects 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- 238000007908 dry granulation Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 238000012546 transfer Methods 0.000 claims description 8
- -1 mixes Substances 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 238000002481 ethanol extraction Methods 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 240000008397 Ganoderma lucidum Species 0.000 abstract 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract 1
- 241000201320 Ligustrum japonicum Species 0.000 abstract 1
- 241001448421 Ophiopogon jaburan Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 241001165494 Rhodiola Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 80
- 241000699670 Mus sp. Species 0.000 description 35
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 24
- 229960004397 cyclophosphamide Drugs 0.000 description 21
- 239000007788 liquid Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 230000001900 immune effect Effects 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000007928 intraperitoneal injection Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical group C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940084983 cyclophosphamide 50 mg Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940100243 oleanolic acid Drugs 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 108010052008 colla corii asini Proteins 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000011091 composite packaging material Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicinal preparation which is prepared from Chinese herbs including ligustrum japonicum, astragalus root, rhizome of Chinese paris, acanthopanax root, ganoderma lucidum, root of herbaceous peony, lilyturf root, rhodiola root, barbat skullcap and poria cocos.
Description
Technical field:
The present invention relates to spirit in a kind of day and reproduce Chinese medicine preparation, particularly use Fructus Ligustri Lucidi, the Radix Astragali, Rhizoma Paridis, Radix Et Caulis Acanthopanacis Senticosi, Ganoderma, the Radix Paeoniae Alba, Radix Ophiopogonis, Radix Rhodiolae, Herba Scutellariae Barbatae, the Chinese medicine preparation that Chinese medicines such as Poria are made.
Background technology:
Prescription of the present invention system sums up on the basis of Chinese medicine malignant tumor clinical experience in recent years, in conjunction with Chinese medicine in recent years the cause of disease, pathogenesis and the method for treatment of malignant tumor and the progress of clinical application are carried out the clinical experience side of prescription by the principles of formulating prescriptions of present science of TCM formulas.And, find to have clinical efficacy preferably by using the clinical verification of decoction.
Chinese prescription of the present invention is made up of 9 flavor Chinese medicines, comprising Yin-nourishing drug 2 flavors, and QI invigorating medicine 4 flavors, heat-clearing and toxic substances removing 2 flavors, other 3 flavor.Its main effect is a benefiting qi and nourishing yin, the detoxifcation of nourishing blood is main, is used for deficiency of both QI and YIN, the concurrent chemoradiotherapy of malignant tumor patient of blood deficiency poison card, the present invention has overcome the defective of prior art, and a kind of determined curative effect, safe ready, little, the cheap pure traditional Chinese compound medicine of side effect are provided.
Summary of the invention:
The invention provides spirit in a kind of day and reproduce Chinese medicine preparation, Chinese medicine preparation of the present invention has benefiting qi and nourishing yin, the effect of the detoxifcation of nourishing blood.Be used for deficiency of both QI and YIN, the malignant tumor chemotherapy patient's of blood deficiency pyretic toxicity card efficacy enhancing and toxicity reducing, disease is seen refreshing weary unable, the lazy speech of breathing hard, dizzy nervous, feel sick, inappetence, vexed sleep poor, dry mouth and tougue, cough, expectorant is few, or thin sputum and gluing, or sputum mixed with blood, sound of cough being low and weak, dyspnea with shortness of breath, red tongue or light red, the tooth seal is arranged, thin fur, thready and weak pulse.
Chinese medicine preparation of the present invention, its prescription is composed as follows:
Fructus Ligustri Lucidi 170-680g Radix Astragali 136-544g Rhizoma Paridis 136-544g Radix Et Caulis Acanthopanacis Senticosi 102-408g
Ganoderma 136-544g Radix Paeoniae Alba 68-272g 136-544g Radix Ophiopogonis Radix Rhodiolae 85-340g
Herba Scutellariae Barbatae 153-612g Poria 102-408g
Most preferred prescription is composed as follows:
Fructus Ligustri Lucidi 340g Radix Astragali 272g Rhizoma Paridis 272g Radix Et Caulis Acanthopanacis Senticosi 204g
Ganoderma 272g Radix Paeoniae Alba 136g 272g Radix Ophiopogonis Radix Rhodiolae 170g
Herba Scutellariae Barbatae 306g Poria 204g
In more than forming, weight is calculated with crude drug, more than form to can be made into 1000 doses of pharmaceutical preparatioies, and described 1000 doses of fingers, the final drug preparation of making, as make 1000 of capsule preparations, 1000 in tablet, granule 1000 grams, oral liquid 1000ml etc.
More than form, as if being unit with the gram, can be made into the preparation of 50-1000 taking dose, as tablet, make 1000, each taking dose can be the 1-20 sheet, can take 50-1000 time altogether.As granule, make 125 bags, take the 1-2 bag at every turn, can take 62.5-125 time altogether.
More than form to be by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production can be unit with the milligram also, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and as serious symptom or light disease, fat or modest patient, the proportioning of the amount of can corresponding adjustment forming increases or reduces being no more than 100%, and drug effect is constant.
Single medicinal material, especially ministerial drug and adjuvant drug in more than forming also can be replaced by the suitable Chinese medicine with identical property of medicine, and its drug effect of the Chinese medicine preparation after the replacement is constant.
Chinese medicine preparation of the present invention is to process through extraction or other modes by the raw material of Chinese medicine that above-mentioned prescription is formed, and makes pharmaceutically active substance, subsequently, with this material is raw material, adds the medicine acceptable carrier when needing, and makes according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting raw material of Chinese medicine respectively, also can obtain by the co-extracted raw material of Chinese medicine, also can obtain by other modes, as: by pulverize, squeeze, calcine, grind, sieve, percolation, extraction, water are carried, alcohol extraction, ester are carried, methods such as ketone is carried, chromatography obtain, these active substances can be the material of extractum form, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
Pharmaceutically active substance in the Chinese medicine preparation of the present invention, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are the medicine acceptable carrier.Pharmaceutical preparation of the present invention exists with unit dosage form, and described unit dosage form is meant the unit of preparation, as every of tablet, and capsular every capsules, every bottle of oral liquid, every bag of granule etc.
Chinese medicine preparation of the present invention can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preparation of the present invention, peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.Granule most preferably.
Chinese medicine preparation of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.
The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.
Can fill by mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Mix repeatedly active substance is distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup or elixir, perhaps can be a kind of available water before use or other suitable composite dry products of carrier.This liquid preparation can contain conventional additive, such as suspending agent, for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat, emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if desired, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, this chemical compound can be suspended or dissolving.The preparation of solution is normally by being dissolved in active substance in a kind of carrier filter-sterilized before it is packed into a kind of suitable bottle or ampoule, sealing then.For example a kind of local anesthetic of adjuvant, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into that this compositions is freezing, and under vacuum, water is removed.
Chinese medicine preparation of the present invention, when being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Preparation of the present invention is determined usage and dosage according to patient's situation in use, but obeys every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet.
Chinese medicine preparation preferred manufacturing procedure of the present invention is as follows:
In the prescription ten flavor medicine, Fructus Ligustri Lucidi, Rhizoma Paridis, Radix Et Caulis Acanthopanacis Senticosi, Radix Rhodiolae four flavors add 70% alcohol reflux twice, each 2.0 hours, 7 times of amounts for the first time, 5 times of amounts filter for the second time, merge filtrate twice, decompression low temperature (0.085Mpa, 70-80 ℃) recovery ethanol gets clear paste I to there not being the alcohol flavor; Medicinal residues are waved most ethanol, add the Radix Astragali, Ganoderma, the Radix Paeoniae Alba, Radix Ophiopogonis, Herba Scutellariae Barbatae, Poria Six-element, decoct with water twice, each 1.5 hours, 11 times of amounts for the first time, 9 times of amounts filter for the second time, filtrate merges, and is evaporated to relative density 1.08-1.10 (60 ℃), gets clear paste II; Merge above-mentioned clear paste I, II, transfer to relative density 1.08-1.10 (60 ℃), spray drying gets spray powder, and this dry powder is active constituents of medicine; This composition is mixed and made into Chinese medicine preparation of the present invention separately or with the medicine acceptable carrier.
Preparation method of the present invention obtains through screening, and we divide into groups medical material according to the physicochemical property of each medical material effective ingredient, and every group is carried out Study on extraction process respectively.It is not soluble in water that main active has part in Fructus Ligustri Lucidi, Rhizoma Paridis, Radix Et Caulis Acanthopanacis Senticosi, the Radix Rhodiolae, dissolves in Different concentrations of alcohol; As triterpenoid compound oleanolic acid, ursolic acid etc., therefore complete in order to guarantee extracts active ingredients, we adopt two lifting manipulations, promptly use earlier the finite concentration ethanol extraction, medicinal residues again with all the other flavour of a drug extracting in waters.The effective ingredient type of Six-element medical materials such as Ganoderma is many, and the polarity scope is big, but most of known effective ingredient is water solublity, and as compositions such as polysaccharide, nucleoside, alkaloid, aminoacid in the monarch drug Ganoderma, therefore can adopt water is that solvent extracts.
For reduce concentrate and drying process in loss of active ingredients, (0.085Mpa), low temperature (＜80 ℃) concentrates and technology such as spray drying to have adopted decompression.Adopt the dry granulation method, have the man-hour of shortening, reduce production costs, reduce supplementary product consumption, improve quality of item, wet, heat-labile medicine is destroyed advantages such as little, still adopt dry granulation.
According to above requirement, we have designed a day spirit and have reproduced particulate preparation technology's flow process, referring to process chart.This extraction process is simple and easy to do, quality controllable, has guaranteed content of effective, has strengthened clinical efficacy.
(1) this part is an index with the oleanolic acid rate of transform, selects L for use
9(3
4) orthogonal table, Fructus Ligustri Lucidi, Radix Et Caulis Acanthopanacis Senticosi, Radix Rhodiolae, Rhizoma Paridis four Chinese medicine have been carried out the ethanol extraction optimal process, investigate the influence of concentration of alcohol, ethanol consumption and return time to process conditions.The result shows that optimised process is: medical material adds 70% alcohol reflux twice, and each 2 hours, add 7 times of amounts for the first time, add 5 times of amounts for the second time, filter, filtrate merges.
(2) L is adopted in this part
9(3
4) orthogonal table preferred the water of Six-element medicines such as alcohol extraction medicinal residues and Ganoderma, the Radix Astragali carry optimum process, serve as to investigate index with the total polysaccharides yield, influence factors such as amount of water, decocting time, decoction number of times are investigated, preferred water is put forward process conditions.The result shows that optimised process is: the medicinal residues behind the four Chinese medicine material ethanol extractions such as Six-element medicines such as Ganoderma adding Fructus Ligustri Lucidi, decoct with water twice, and each 1.5 hours, add 11 times of water gagings for the first time, add 9 times of water gagings for the second time, decocting liquid filters, and filtrate merges.
(3) this part is an index with the oleanolic acid rate of transform, has investigated the influence that concentrates under normal pressure and the reduced pressure effective ingredient.The result shows: concentrating under reduced pressure (temperature is at 70～80 ℃), loss of effective components is less.
(4) the spray drying condition has been investigated in this part, is index with spray powder granularity etc., carries out the screening of clear paste relative density, the result: the relative density that concentrates clear paste is chosen 1.08～1.10 (20 ℃), atomizes when dry, and granularity is moderate.
(5) exsiccant inlet temperature in the spray drying condition, leaving air temp, tower internal pressure, charging rate etc. have been investigated in this part, and inlet temperature is selected 165 ℃ as a result, and leaving air temp is selected 85 ℃.
(6) screening of dry granulation condition is carried out according to the characteristics and the requirement of prescription in this part, adopts rolling process to granulate; Regulate the tabletting thickness of dry granulation machine, pressure is pressed into the bar shaped thin slice with fine powder, pulverizes, and mistake classifying screen (20 orders, 60 orders) was got 20 orders and 60 purpose granules are standby.
(7) this part is according to the character and the stability requirement of this preparation: granule should be preserved under the condition of sealing.Investigated the composite packaging material of multiple medicinal aluminum-plastic composite membrane and packed, by comparing, we select composite membrane for use--polyester/aluminium/polyethylene Medicine Package Bag.
Below by pharmacodynamics test beneficial effect of the present invention is described.
The experiment medicine is the medicine of the embodiment of the invention 1 method preparation, and at this called after: granule is reproduced in a day spirit.
(1) eliminating evil effect
1, to mice S
180The influence of sarcoma
S has been inoculated in extraction under the aseptic condition
1807 days tumor-bearing mice ascites is separated oncocyte, adjusts cell number 2 * 10 with normal saline
7Individual/ml, expect that with 2% platform blue dyeing carries out viable count (living cell rate＞95%).Under the aseptic condition in the right axil subcutaneous vaccination of mice 0.2ml/ only, be divided into 5 groups after 24 hours at random, every group 10, be respectively model control group, a day spirit reproduce the granule small dose group (2.5g crude drug/kg), a day spirit reproduce dosage group in the granule (5g crude drug/kg), a day spirit reproduce the heavy dose of group of granule (10g crude drug/kg) and positive drug cyclophosphamide group (and 50mg/kg, ip).Except that the positive drug lumbar injection, all the other each administration group gastric infusions every day, capacity is the 0.2ml/10g body weight, model control group waits the capacity distilled water, successive administration 10 days, next day is put to death mice in drug withdrawal, and mice is put to death in the back of weighing, peel off the subcutaneous tumors piece, claim tumor heavy, be calculated as follows tumour inhibiting rate.From the result as seen, granule (2.5g crude drug/kg, 5g crude drug/kg, 10g crude drug/kg) to mice S are reproduced in a day spirit
180The growth of sarcoma has obvious inhibitory action.
2, to the influence of mice ehrlich ascites tumor.
Get inoculation ehrlich ascites tumor cell 8 days mouse ascites under the aseptic condition, separate oncocyte, adjust 2 * 107/ml of cell number, expect that with 2% platform blue dyeing carry out viable count (living cell rate＞95%) with normal saline.Only inoculate 0.2ml/ in mouse peritoneal under the aseptic condition, after 24 hours, be divided into 5 groups at random, every group 10, be respectively model control group, a day spirit reproduce the granule small dose group (2.5g crude drug/kg), a day spirit reproduce dosage group in the granule (5g crude drug/kg), a day spirit reproduce the heavy dose of group of granule (10g crude drug/kg) and positive drug cyclophosphamide group (and 50mg/kg, sc).Except that the positive drug subcutaneous injection, all the other each administration group gastric infusions every day, capacity is the 0.2ml/10g body weight, model control group waits the capacity distilled water, and administration every day (water) is once observed and the record death time of animal, calculate the existence natural law, be calculated as follows increase in life span.This result of the test shows that granule (5g crude drug/kg, 10g crude drug/kg) can prolong ehrlich ascites tumor mice existence natural law are reproduced in a day spirit.
(2) potentiation
S has been inoculated in extraction under the aseptic condition
1807 days tumor-bearing mice ascites is separated oncocyte, adjusts cell number 2 * 10 with normal saline
7Individual/ml, expect that with 2% platform blue dyeing carries out viable count (living cell rate＞95%).It is subcutaneous to get the right axil of 0.2ml injection mice under the aseptic condition, be divided into 5 groups after 24 hours at random, every group is 10, be respectively model control group, cyclophosphamide group (50mg/kg, ip), granule small dose group (2.5g crude drug/kg is reproduced in a day spirit, while ip cyclophosphamide 50mg/kg), dosage group in the granule (5g crude drug/kg, ip cyclophosphamide 50mg/kg simultaneously) is reproduced in a day spirit, a day spirit is reproduced the granule heavy dose and organized (10g crude drug/kg, ip cyclophosphamide 50mg/kg simultaneously).Administration group gastric infusion every day, capacity are the 0.2ml/10g body weight, and model control group waits the capacity distilled water, and continuous 10 days, drug withdrawal was taken off cervical vertebra next day and put to death mice, weigh and peel off the subcutaneous tumors piece, claim tumor heavy, are calculated as follows tumour inhibiting rate.This result of the test shows that granule (2.5g crude drug/kg, 5g crude drug/kg, 10g crude drug/when kg) share with cyclophosphamide, can obviously strengthen the tumor-inhibiting action of cyclophosphamide are reproduced in a day spirit.
(3) centralizing function
1, to the influence of immunologic hypofunction mice serum hemolysin content.
Get 60 mices, be divided into 6 groups at random, every group 10, be respectively normal control group, model control group, a day spirit and reproduce the granule small dose group (dosage group in the granule is reproduced in 2.5g crude drug/kg), a day spirit, and (the heavy dose of group of granule (10g crude drug/kg) and positive drug levamisole group (50mg/kg) are reproduced in 5g crude drug/kg), a day spirit.Except that the normal control group, all the other are respectively organized equal subcutaneous injection cyclophosphamide (80mg/kg) and cause immunologic hypofunction, administration group gastric infusion every day, capacity is the 0.2ml/10g body weight, the normal control group, model control group waits the capacity normal saline every day, after the administration 3 days, (v: v) Xi Shi sheep red blood cell (SRBC) suspension 0.2ml/ only carried out immunity to each treated animal lumbar injection in 3: 5, continue administration 7 days, the last administration was extractd eyeball of mouse respectively and is got blood after 2 hours, separation of serum, after doing 500 times of dilutions, under GPC participates in, do hemolysin and measure, calculate half hemolysis value.This result of the test shows, granule is reproduced in a day spirit, and (2.5g crude drug/kg, 5g crude drug/kg, 10g crude drug/kg) can make cyclophosphamide cause immunologic hypofunction mice serum hemolysin content obviously raise.
2. to the influence of immunologic hypofunction functions of murine peritoneal macrophages
Mice is divided into 6 groups at random, every group 10, being respectively normal control group, model control group, a day spirit reproduces the granule small dose group (dosage group in the granule is reproduced in 2.5g crude drug/kg), a day spirit, and (the heavy dose of group of granule (10g crude drug/kg) and positive drug positive drug levamisole group (50mg/kg) is reproduced in 5g crude drug/kg), a day spirit, the continuous gastric infusion of administration group 7 days, once a day, capacity is the 0.2ml/10g body weight, and the blank group gives the equivalent distilled water.While subcutaneous injection cyclophosphamide 80mg/kg (except the normal control group), capacity is the 0.1ml/10g body weight.After the last administration 30 minutes, each chicken erythrocyte suspension (CRBC) 0.4ml/ that organizes the equal lumbar injection 5% of mice only, after 8 hours, take off cervical vertebra and put to death mice, cut off skin of abdomen, intraperitoneal injection of saline 2ml, behind the soft mouse web portion, draw peritoneal irrigation liquid smear, dry back Giemsa-wright dyeing, oily sem observation.Count 200 macrophages, calculate phagocytic percentage and phagocytic index.This result of the test shows: granule is reproduced in a day spirit, and (2.5g crude drug/kg, 5g crude drug/kg, 10g crude drug/kg) all can improve immunologic hypofunction Turnover of Mouse Peritoneal Macrophages phagocytic function.
3. the influence that the immunologic hypofunction mouse spleen lymphocyte is transformed
Get 60 of mices, be divided into 6 groups at random, every group 10, be respectively normal control group, model control group, a day spirit and reproduce the granule small dose group (dosage group in the granule is reproduced in 2.5g crude drug/kg), a day spirit, and (the heavy dose of group of granule (10g crude drug/kg) and positive drug levamisole group (50mg/kg) are reproduced in 5g crude drug/kg), a day spirit.The experiment beginning, except that the normal control group, all the other are respectively organized equal subcutaneous injection cyclophosphamide (80mg/kg) and cause immunologic hypofunction.Administration group successive administration 10 days, capacity are the 0.2ml/10g body weight, after the last administration 2 hours, put to death mice, and aseptic condition takes out spleen down, shreds 200 eye mesh screens, and using Hank ' s liquid furnishing concentration is 2 * 10
6The splenocyte suspension of/ml.In 24 well culture plates, every hole adds splenocyte suspension 1ml (every Mus takies 2 holes), and wherein 1 hole adds 50ulConA (5ug/ml), and Kong Bujia puts 37 ℃ and contains 5%CO in contrast in addition
2In the incubator 72 hours, to cultivate and finish preceding 4 hours, every hole is inhaled and is abandoned supernatant 0.7ml, adds the RPMI1640 culture fluid 0.7ml that does not contain calf serum, and adding concentration simultaneously is the MTT liquid 50ul/ hole of 5mg/ml.Continue to cultivate after 4 hours, take out culture plate and crystallization is fully dissolved to every hole adding 1ml acid isopropyl alcohol and vibration.Draw culture fluid to the 1ml cuvette by every hole, measure the OD value in 722 spectrophotometers.This result of the test shows, granule is reproduced in it spirit, and (2.5g crude drug/kg, 5g crude drug/kg, 10g crude drug/kg) can make cyclophosphamide cause immunologic hypofunction mouse spleen lymphocyte conversion ratio obviously increase, and show that a day spirit reproduces granule and can improve immunologic hypofunction mouse cell immunologic function.
(4) Attenuation
1. a day spirit is reproduced granule cyclophosphamide is caused the influence that murine interleukin reduces
Get 60 mices and be divided into 6 groups at random, every group 10, be respectively normal control group, model control group, a day spirit and reproduce the granule small dose group (dosage group in the granule is reproduced in 2.5g crude drug/kg), a day spirit, and (the heavy dose of group of granule (10g crude drug/kg) and positive drug FUFANG EJIAO JIANG group (8.6mg/kg) are reproduced in 5g crude drug/kg), a day spirit.Except that the normal control group, all the other respectively organize all intraperitoneal injection of cyclophosphamide (100mg/kg) for three days on end of mice
[5], the group of administration simultaneously gastric infusion every day, capacity is the 0.2ml/10g body weight, normal control group and model control group wait the capacity distilled water, continuous 10 days.After the last administration 40 minutes, eye socket blood sampling counting peripheral blood leucocyte.From the result as seen, respectively organize rat leukocyte before the administration and count no significant difference, the obviously normal control rats few (p＜0.01) of model group rat leukocyte number after the administration, granule is reproduced in it spirit, and (2.5g crude drug/kg, 5g crude drug/kg, 10g crude drug/kg) organize the obviously normal control rats many (p＜0.05 or p＜0.01) of rat leukocyte number show that it causes the murine interleukin minimizing to cyclophosphamide obvious reverse effect is arranged.
2, a day spirit is reproduced granule cyclophosphamide is caused the influence that the mice food-intake reduces
Get 60 mices and be divided into 6 groups at random, single cage is raised, every group 10, be respectively the normal control group, model control group (intraperitoneal injection of cyclophosphamide 20mg/kg, the next day once totally 5 times), granule small dose group (2.5g crude drug/kg is reproduced in it spirit, while intraperitoneal injection of cyclophosphamide 20mg/kg, the next day once totally 5 times), dosage group (5g crude drug/kg in the granule is reproduced in it spirit, while intraperitoneal injection of cyclophosphamide 20mg/kg, the next day once totally 5 times), the heavy dose of group of granule (10g crude drug/kg is reproduced in it spirit, while intraperitoneal injection of cyclophosphamide 20mg/kg, the next day once totally 5 times) and positive drug FUFANG EJIAO JIANG (8.6ml/kg, intraperitoneal injection of cyclophosphamide 20mg/kg simultaneously, the next day once totally 5 times).Administration group gastric infusion every day, capacity are the 0.2ml/10g body weight, and normal control group and model control group wait the capacity distilled water, continuous 10 days.Respectively organizing the mice food-intake next day of before the record administration and behind the medicine changes.From the result as seen, the obviously normal control group mice few (p＜0.01) of model group mice food-intake, granule is reproduced in it spirit, and (2.5g crude drug/kg, 5g crude drug/kg, 10g crude drug/kg) group mice food-intake 4d, 6d, 8d, 10d time point behind medicine shows that all obviously than model control group mice many (p＜0.01) it causes the minimizing of mice food-intake to cyclophosphamide and is significantly increased effect.
Acute toxicity testing
According to the requirement of " provisions for new drugs approval ", spirit is reproduced granule and has been carried out acute toxicity test in mice to the sky, because of measuring LD
50So, carried out the mensuration of the maximum dosage-feeding of mouse stomach administration, mouse stomach administration as a result, maximum dosage-feeding is 160g crude drug/kg, be equivalent to be grown up 160 times (clinical adult 70kg, consumption 68g crude drugs/day) of clinical consumption, untoward reaction and death do not appear in animal.
Long term toxicity test
120 of experimental applications SD rats, carry out long term toxicity test research, rat is divided into four groups at random, every group 40, be respectively the normal control group, granule small dose group (10g crude drug/kg is reproduced in it spirit, be equivalent to 10 times of clinical application), dosage group (20g crude drug/kg in the granule is reproduced in it spirit, be equivalent to 20 times of clinical application), the heavy dose of group of granule (40g crude drug/kg is equivalent to 40 times of clinical application) is reproduced in a day spirit, continuously 26 weeks of gastric infusion, observe a day spirit and reproduce the influence of granule the every index of animal.Result of the test shows, the result shows, granule is reproduced in day spirit, and (10g crude drug/kg, 20g crude drug/kg, 40g crude drug/kg) all do not have obvious influence to the general situation of rat, body weight, hematological indices, ten biochemical indicators and main organs coefficient; Each internal organs naked eyes and mirror are observed down, also do not have obvious pathological change.Show that this medicine does not have the overt toxicity reaction, its nontoxic amounts of reactants is 40g crude drug/kg/ day, can recommend clinical use.
In sum, a day spirit is reproduced granule (2.5g crude drug/kg, 5g crude drug/kg, 10g crude drug/kg) to mice S
180The growth of sarcoma has obvious inhibitory action; Can prolong ehrlich ascites tumor mice existence natural law; Share mice S with the chemotherapeutic cyclophosphamide
180The inhibition of sarcoma has the notable synergistic effect; Can make cyclophosphamide cause immunologic hypofunction mice serum hemolysin content and obviously raise, the splenocyte conversion ratio obviously increases; Cyclophosphamide is caused the murine interleukin minimizing reverse effect, and cyclophosphamide is caused the minimizing of mice food-intake the increase effect.Result of study provides necessary theoretical foundation for clinical application.Toxicologic study shows that also this medicine does not have the overt toxicity reaction, and therefore, pharmaceutical preparation of the present invention has good therapeutical effect.
The specific embodiment:
Further specify the present invention by the following examples, but not as limitation of the present invention.
Embodiment 1
Prescription: Fructus Ligustri Lucidi 340g Radix Astragali 272g Rhizoma Paridis 272g Radix Et Caulis Acanthopanacis Senticosi 204g
Ganoderma 272g Radix Paeoniae Alba 136g 272g Radix Ophiopogonis Radix Rhodiolae 170g
Herba Scutellariae Barbatae 306g Poria 204g
Preparation technology
More than ten flavors, Fructus Ligustri Lucidi, Rhizoma Paridis, Radix Et Caulis Acanthopanacis Senticosi, Radix Rhodiolae four flavors add 70% alcohol reflux twice, each 2.0 hours, 7 times of amounts for the first time, 5 times of amounts filter for the second time, merge filtrate twice, decompression low temperature (0.085Mpa, 70-80 ℃) recovery ethanol gets clear paste I to there not being the alcohol flavor; Medicinal residues are waved most ethanol, add the Radix Astragali, Ganoderma, the Radix Paeoniae Alba, Radix Ophiopogonis, Herba Scutellariae Barbatae, Poria Six-element, decoct with water twice, each 1.5 hours, 11 times of amounts for the first time, 9 times of amounts filter for the second time, filtrate merges, and is evaporated to relative density 1.08-1.10 (60 ℃), gets clear paste II; Merge above-mentioned clear paste I, II, transfer to relative density 1.08-1.10 (60 ℃), spray drying gets spray powder, adds an amount of dextrin, steviosin, dry granulation, and granulate, packing, promptly.
Embodiment 2
Prescription:
Fructus Ligustri Lucidi 170g Radix Astragali 136g Rhizoma Paridis 136g Radix Et Caulis Acanthopanacis Senticosi 102g
Ganoderma 136g Radix Paeoniae Alba 68g 136g Radix Ophiopogonis Radix Rhodiolae 85g
Herba Scutellariae Barbatae 153g Poria 102g
Preparation technology
More than ten flavors, Fructus Ligustri Lucidi, Rhizoma Paridis, Radix Et Caulis Acanthopanacis Senticosi, Radix Rhodiolae four flavors add 70% alcohol reflux twice, each 2.0 hours, 7 times of amounts for the first time, 5 times of amounts filter for the second time, merge filtrate twice, decompression low temperature (0.085Mpa, 70-80 ℃) recovery ethanol gets clear paste I to there not being the alcohol flavor; Medicinal residues are waved most ethanol, add the Radix Astragali, Ganoderma, the Radix Paeoniae Alba, Radix Ophiopogonis, Herba Scutellariae Barbatae, Poria Six-element, decoct with water twice, each 1.5 hours, 11 times of amounts for the first time, 9 times of amounts filter for the second time, filtrate merges, and is evaporated to relative density 1.08-1.10 (60 ℃), gets clear paste II; Merge above-mentioned clear paste I, II, transfer to relative density 1.08-1.10 (60 ℃), spray drying gets spray powder, adds an amount of dextrin, steviosin, dry granulation, and granulate, packing, promptly.
Embodiment 3
Prescription:
Fructus Ligustri Lucidi 680g Radix Astragali 544g Rhizoma Paridis 544g Radix Et Caulis Acanthopanacis Senticosi 408g
Ganoderma 544g Radix Paeoniae Alba 272g 544g Radix Ophiopogonis Radix Rhodiolae 340g
Herba Scutellariae Barbatae 612g Poria 408g
Preparation technology
More than ten flavors, Fructus Ligustri Lucidi, Rhizoma Paridis, Radix Et Caulis Acanthopanacis Senticosi, Radix Rhodiolae four flavors add 70% alcohol reflux twice, each 2.0 hours, 7 times of amounts for the first time, 5 times of amounts filter for the second time, merge filtrate twice, decompression low temperature (0.085Mpa, 70-80 ℃) recovery ethanol gets clear paste I to there not being the alcohol flavor; Medicinal residues are waved most ethanol, add the Radix Astragali, Ganoderma, the Radix Paeoniae Alba, Radix Ophiopogonis, Herba Scutellariae Barbatae, Poria Six-element, decoct with water twice, each 1.5 hours, 11 times of amounts for the first time, 9 times of amounts filter for the second time, filtrate merges, and is evaporated to relative density 1.08-1.10 (60 ℃), gets clear paste II; Merge above-mentioned clear paste I, II, transfer to relative density 1.08-1.10 (60 ℃), spray drying gets spray powder, adds an amount of dextrin, steviosin, dry granulation, and granulate, packing, promptly.
Embodiment 4
Prescription: Fructus Ligustri Lucidi 340g Radix Astragali 272g Rhizoma Paridis 272g Radix Et Caulis Acanthopanacis Senticosi 204g
Ganoderma 272g Radix Paeoniae Alba 136g 272g Radix Ophiopogonis Radix Rhodiolae 170g
Herba Scutellariae Barbatae 306g Poria 204g
Preparation technology
More than ten flavors, Fructus Ligustri Lucidi, Rhizoma Paridis, Radix Et Caulis Acanthopanacis Senticosi, Radix Rhodiolae four flavors add 70% alcohol reflux twice, each 2.0 hours, 7 times of amounts for the first time, 5 times of amounts filter for the second time, merge filtrate twice, decompression low temperature (0.085Mpa, 70-80 ℃) recovery ethanol gets clear paste I to there not being the alcohol flavor; Medicinal residues are waved most ethanol, add the Radix Astragali, Ganoderma, the Radix Paeoniae Alba, Radix Ophiopogonis, Herba Scutellariae Barbatae, Poria Six-element, decoct with water twice, each 1.5 hours, 11 times of amounts for the first time, 9 times of amounts filter for the second time, filtrate merges, and is evaporated to relative density 1.08-1.10 (60 ℃), gets clear paste II; Merge above-mentioned clear paste I, II, transfer to relative density 1.08-1.10 (60 ℃), spray drying gets spray powder, adds appropriate amount of starch, and adjuvants such as magnesium stearate are granulated, granulate, and tabletting, promptly.
Embodiment 5
Prescription: Fructus Ligustri Lucidi 340g Radix Astragali 272g Rhizoma Paridis 272g Radix Et Caulis Acanthopanacis Senticosi 204g
Ganoderma 272g Radix Paeoniae Alba 136g 272g Radix Ophiopogonis Radix Rhodiolae 170g
Herba Scutellariae Barbatae 306g Poria 204g
Preparation technology
More than ten flavors, Fructus Ligustri Lucidi, Rhizoma Paridis, Radix Et Caulis Acanthopanacis Senticosi, Radix Rhodiolae four flavors add 70% alcohol reflux twice, each 2.0 hours, 7 times of amounts for the first time, 5 times of amounts filter for the second time, merge filtrate twice, decompression low temperature (0.085Mpa, 70-80 ℃) recovery ethanol gets clear paste I to there not being the alcohol flavor; Medicinal residues are waved most ethanol, add the Radix Astragali, Ganoderma, the Radix Paeoniae Alba, Radix Ophiopogonis, Herba Scutellariae Barbatae, Poria Six-element, decoct with water twice, each 1.5 hours, 11 times of amounts for the first time, 9 times of amounts filter for the second time, filtrate merges, and is evaporated to relative density 1.08-1.10 (60 ℃), gets clear paste II; Merge above-mentioned clear paste I, II, transfer to relative density 1.08-1.10 (60 ℃), spray drying gets spray powder, adds appropriate amount of starch, and adjuvants such as magnesium stearate are granulated, granulate, and the capsule of packing into No. 1, promptly.
Embodiment 6
Prescription: Fructus Ligustri Lucidi 340g Radix Astragali 272g Rhizoma Paridis 272g Radix Et Caulis Acanthopanacis Senticosi 204g
Ganoderma 272g Radix Paeoniae Alba 136g 272g Radix Ophiopogonis Radix Rhodiolae 170g
Herba Scutellariae Barbatae 306g Poria 204g
Preparation technology
More than ten flavors, Fructus Ligustri Lucidi, Rhizoma Paridis, Radix Et Caulis Acanthopanacis Senticosi, Radix Rhodiolae four flavors add 70% alcohol reflux twice, each 2.0 hours, 7 times of amounts for the first time, 5 times of amounts filter for the second time, merge filtrate twice, decompression low temperature (0.085Mpa, 70-80 ℃) recovery ethanol gets clear paste I to there not being the alcohol flavor; Medicinal residues are waved most ethanol, add the Radix Astragali, Ganoderma, the Radix Paeoniae Alba, Radix Ophiopogonis, Herba Scutellariae Barbatae, Poria Six-element, decoct with water twice, each 1.5 hours, 11 times of amounts for the first time, 9 times of amounts filter for the second time, filtrate merges, and is evaporated to relative density 1.08-1.10 (60 ℃), gets clear paste II; Merge above-mentioned clear paste I, II, transfer to relative density 1.08-1.10 (60 ℃), add an amount of sucrose, antiseptic adds water to 1000ml, is distributed into one of 10ml, promptly gets oral liquid.
Claims (8)
1. a Chinese medicine preparation for the treatment of malignant tumor is characterized in that, is made by following Chinese medicinal raw materials
Fructus Ligustri Lucidi 170-680g Radix Astragali 136-544g Rhizoma Paridis 136-544g Radix Et Caulis Acanthopanacis Senticosi 102-408g
Ganoderma 136-544g Radix Paeoniae Alba 68-272g 136-544g Radix Ophiopogonis Radix Rhodiolae 85-340g
Herba Scutellariae Barbatae 153-612g Poria 102-408g.
2. the Chinese medicine preparation of claim 1 is characterized in that, is made by following Chinese medicinal raw materials
Fructus Ligustri Lucidi 340g Radix Astragali 272g Rhizoma Paridis 272g Radix Et Caulis Acanthopanacis Senticosi 204g
Ganoderma 272g Radix Paeoniae Alba 136g 272g Radix Ophiopogonis Radix Rhodiolae 170g
Herba Scutellariae Barbatae 306g Poria 204g.
3. the Chinese medicine preparation of claim 1 is characterized in that, is selected from tablet, capsule, granule, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, suppository, drop pill or patch.
4. the Chinese medicine preparation of claim 1 is a granule.
5. the preparation method of the Chinese medicine preparation of claim 1 is characterized in that, the process following steps:
Fructus Ligustri Lucidi, Rhizoma Paridis, Radix Et Caulis Acanthopanacis Senticosi, Radix Rhodiolae four flavors, ethanol extraction reclaims ethanol, gets clear paste I; The medicinal residues and the Radix Astragali, Ganoderma, the Radix Paeoniae Alba, Radix Ophiopogonis, Herba Scutellariae Barbatae, Poria Six-element decoct with water, and concentrate, and get clear paste II; Merge clear paste I, II and promptly get active constituents of medicine; This composition is mixed and made into Chinese medicine preparation separately or with the medicine acceptable carrier.
6. the preparation method of the Chinese medicine preparation of claim 5 is characterized in that, the process following steps:
Fructus Ligustri Lucidi, Rhizoma Paridis, Radix Et Caulis Acanthopanacis Senticosi, Radix Rhodiolae four flavors add 70% alcohol reflux twice, each 2.0 hours, 7 times of amounts for the first time, 5 times of amounts filter for the second time, merge filtrate twice, decompression low temperature reclaims ethanol to there not being the alcohol flavor, clear paste I; Medicinal residues are waved most ethanol, add the Radix Astragali, Ganoderma, the Radix Paeoniae Alba, Radix Ophiopogonis, Herba Scutellariae Barbatae, Poria Six-element, decoct with water twice, each 1.5 hours, 11 times of amounts for the first time, 9 times of amounts filter for the second time, filtrate merges, and is evaporated to relative density 1.08～1.10, gets clear paste II; Merge above-mentioned clear paste I, II, transfer to relative density 1.08～1.10, spray drying gets spray powder, and this dry powder is active constituents of medicine; This composition is mixed and made into Chinese medicine preparation of the present invention separately or with the medicine acceptable carrier.
7. the preparation method of the Chinese medicine preparation of claim 6 is characterized in that, and is described or be mixed and made into Chinese medicine preparation of the present invention with the medicine acceptable carrier, is active constituents of medicine and an amount of dextrin, steviosin, mixes, and granulates granulate, packing with the dry granulation method.
8. the application of the Chinese medicine preparation of claim 1 in the medicine of preparation treatment malignant tumor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101618312A CN1970034B (en) | 2006-12-05 | 2006-12-05 | Chinese medicine containing gadol and tuckahoe |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101618312A CN1970034B (en) | 2006-12-05 | 2006-12-05 | Chinese medicine containing gadol and tuckahoe |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1970034A CN1970034A (en) | 2007-05-30 |
| CN1970034B true CN1970034B (en) | 2011-09-07 |
Family
ID=38111182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006101618312A Expired - Fee Related CN1970034B (en) | 2006-12-05 | 2006-12-05 | Chinese medicine containing gadol and tuckahoe |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1970034B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296823A (en) * | 2000-05-09 | 2001-05-30 | 张丽莉 | Antineoplastic Chinese medicine and its preparing process |
| CN1421238A (en) * | 2002-12-23 | 2003-06-04 | 丁铁岭 | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity |
-
2006
- 2006-12-05 CN CN2006101618312A patent/CN1970034B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296823A (en) * | 2000-05-09 | 2001-05-30 | 张丽莉 | Antineoplastic Chinese medicine and its preparing process |
| CN1421238A (en) * | 2002-12-23 | 2003-06-04 | 丁铁岭 | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity |
Non-Patent Citations (1)
| Title |
|---|
| 江翠红，丁爱国.天灵再造液治疗急性缺血性中风临床观察.《中国中医急症》.2006,第15卷(第9期),937. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1970034A (en) | 2007-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101239112B (en) | Traditional Chinese medicine composition for regulating blood lipid and preparation method thereof | |
| CN104435749B (en) | A kind of dendrobium candidum compound preparation and its preparation method and application | |
| CN112972547A (en) | Traditional Chinese medicine composition for treating qi-blood deficiency syndrome and preparation method and application thereof | |
| CN102271698A (en) | Pharmaceutical composition and its use in the preparation of medicament | |
| CN102106965B (en) | Composition for treating acute injury of soft tissue and application thereof | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN102048890A (en) | Traditional Chinese medicine composition with galactagogue effect and preparation method thereof | |
| CN102858359B (en) | Medicinal composition comprising alcohol-soluble and water-insoluble licorice extract, pharmaceutical preparation, pharmaceutical application, therapeutic method, and preparative method thereof | |
| CN1970034B (en) | Chinese medicine containing gadol and tuckahoe | |
| CN1970032B (en) | Chinese medicine containing honeysuckle flower and weeping forsythia for treating cold | |
| CN1330345C (en) | Combination of Chinese traditional medicine for treating hyperlipemia, and preparation method | |
| CN111375035A (en) | Preparation and application of enteric-coated preparation for treating cervical spondylosis | |
| CN111558019B (en) | Traditional Chinese medicine composition with effects of benefiting qi, nourishing blood, regulating menstruation and relieving pain and preparation method and application thereof | |
| CN107536016B (en) | A nutritional food for protecting heart and promoting liver health | |
| CN119424562B (en) | A traditional Chinese medicine composition, preparation and application for treating drug-induced renal injury | |
| CN104491318A (en) | Traditional Chinese preparation used for treating asthma and preparation method of traditional Chinese preparation | |
| CN100376282C (en) | A medicine for treating spleen-stomach disharmony, appetizing and invigorating spleen | |
| CN113995806B (en) | Traditional Chinese medicine composition for treating lung cancer and application thereof | |
| CN100482264C (en) | Shenling Chinese medicine preparation for strengthening body resistance | |
| CN107158062B (en) | Tumor adjuvant therapy medicine and application thereof | |
| CN1291722C (en) | Use of oligoxylose in preparing medicine for treating diabetes | |
| CN105250919B (en) | It is a kind of for preventing and/or the Chinese medicine composition for treating liver disease and preparation method thereof | |
| CN100371002C (en) | A traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases and its preparation method | |
| CN113274451A (en) | A Chinese medicinal composition with lung and kidney invigorating, heat phlegm clearing away, antitussive, and antiasthmatic effects | |
| CN104352974A (en) | Ciliatenerve knotweed root-containing traditional Chinese medicine composition for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110907 Termination date: 20121205 |